Skip to main content Back to Top
Advertisement

7/18/2019

Carbidopa and Levodopa Extended-Release Tablets

Products Affected - Description

    • Sinemet CR extended release tablet, Merck, 25 mg/100 mg, bottle, 100 count, NDC 00006-3919-68 - discontinued
    • Sinemet CR extended release tablet, Merck, 50 mg/200 mg, bottle, 100 count, NDC 00006-3918-68 - discontinued
    • Carbidopa and Levodopa extended release tablet, Accord, 50 mg/200 mg, bottle, 100 count, NDC 16729-0079-01
    • Carbidopa and Levodopa extended release tablet, Accord, 50 mg/200 mg, bottle, 1000 count, NDC 16729-0079-17

Reason for the Shortage

    • Accord has discontinued carbidopa and levodopa 25 mg/100 mg extended-release tablets. The 50 mg/200 mg tablets are on shortage due to problems obtaining active ingredient.
    • Sun Pharma had carbidopa and levodopa extended-release tablets on shortage due to increased demand.
    • Merck discontinued Sinemet CR in July 2019.
    • Mylan refuses to provide availability information.

Available Products

    • Carbidopa and Levodopa extended release tablet, Sun Pharma, 25 mg/100 mg, 100 count, NDC 62756-0461-88
    • Carbidopa and Levodopa extended release tablet, Sun Pharma, 50 mg/200 mg, 100 count, NDC 62756-0457-88

Estimated Resupply Dates

    • Accord has carbidopa and levodopa 50 mg/200 mg extended-release tablets on allocation.
    • Merck has Sinemet CR 25 mg/100 mg extended release tablets in 100 count bottles on back order and the company cannot estimate a release date.

Updated

Updated July 18, 2019 by Michelle Wheeler, PharmD, Drug Information Specialist. Created September 28, 2017 by Leslie Jensen, PharmD, Drug Information Specialist. © 2019, Drug Information Service, University of Utah, Salt Lake City, UT.

Disclaimer

This information is provided through the support of Vizient to ASHP solely as a service to its members, which shall not use this information for their further commercial use. The content was prepared by the Drug Information Center of University of Utah. Vizient, ASHP, and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, which respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither Vizient, ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this bulletin. Neither Vizient, ASHP nor University of Utah endorses or recommends the use of any drug.

« Back to Drug Shortage Product Bulletins